Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... leukemia (AML) with disease features as described in the protocol . Acute lymphoblastic leukemia (ALL) with disease features as described in the protocol. Myelodysplasia with disease features as described in the ...

    Clinical Trial last updated 06/06/2016 - 3:37pm.

  2. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... leukemia (AML) with disease features as described in the protocol . Acute lymphoblastic leukemia (ALL) with disease features as described in the protocol. Myelodysplasia with disease features as described in the ...

    Clinical Trial last updated 06/03/2016 - 2:54pm.

  3. Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

    ... contributed to this high incidence of cGVHD. In this protocol , we attempt to prevent graft failure and to reduce the incidence ... using the identical conditioning regimen utilized in protocol 99-H-0050. Using the Miltenyi CliniMACs system, recipients will ...

    Clinical Trial last updated 04/28/2016 - 2:40pm.

  4. Clinical Trial Basics

    ... research is done according to a detailed plan known as a protocol . The protocol is carefully designed to safeguard the participants’ health and answer specific research questions. A protocol describes the following: Who is eligible to participate in the ...

    Page last updated 03/29/2016 - 7:29pm.

  5. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must ... Human Services. Approval for the use of this treatment protocol by the individual institution's Human Rights Committee must be ...

    Clinical Trial last updated 06/13/2016 - 2:06pm.

  6. GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

    ... for autologous transplant or a higher priority protocol . Myelodysplastic syndrome (MDS): RA/RCMD with high risk ... evolved from MDS, who are not eligible for a higher priority protocol. Chronic myelomonocytic leukemia: CMML-1 and CMML-2, advanced ...

    Clinical Trial last updated 04/29/2016 - 12:40pm.

  7. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    Journal Title:  Ann Hematol Primary Author:  Mittelman M Author(s):  Mittelma...

    Research Article last updated 09/13/2016 - 2:47pm.

  8. Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

    ... Patient must have received crenolanib on this protocol prior to HSCT to continue on to maintenance. Patient must be ... (HSCT). Response to previous treatment on this protocol: at least resistant disease with clinical benefit or better response. ...

    Clinical Trial last updated 06/06/2016 - 10:04am.

  9. An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia

    ... of adequate method of contraception are shown in the protocol section 4.1.10 Women are considered post-menopausal and not of ... Patients unwilling or unable to comply with the protocol . Pregnant or breastfeeding Acute promyelocytic leukemia ...

    Clinical Trial last updated 06/06/2016 - 1:26pm.

  10. Transplants With Unlicensed Preserved Cord Blood

    ... if the transplant will occur under an IND research protocol . These units are in current and future inventory at domestic and ... Indications. This study is an access and distribution protocol conducted by the National Marrow Donor Program (NMDP) for unlicensed ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.